Centogene (CNTGF) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Centogene has announced compelling findings in ‘The Lancet Neurology’ from its Rostock International Parkinson’s Disease (ROPAD) Study, revealing a significant association between Parkinson’s disease and a genetic mutation in the RAB32 gene. The study, leveraging Whole Genome Sequencing of 3,354 patients, found the RAB32 mutation to be 100 times more prevalent in Parkinson’s patients compared to the general population, underscoring its potential as a target for developing treatments. Additionally, Centogene has initiated a ROPAD Consortium to further Parkinson’s research and improve treatment by utilizing their extensive network and genetic testing program.
For further insights into CNTGF stock, check out TipRanks’ Stock Analysis page.